During his keynote speech at the National Comprehensive Cancer Network (NCCN)'s 20th Annual Conference, Chief Executive Officer Robert Carlson, MD, spent the majority of his time discussing the NCCN Guidelines because they are the core of its services.
During his keynote speech at the National Comprehensive Cancer Network (NCCN)’s 20th Annual Conference, Chief Executive Officer Robert Carlson, MD, spent the majority of his time discussing the NCCN Guidelines because they are the core of its services.
At the annual meeting, held March 12-14 in Hollywood, Florida, NCCN will unveil its Guidelines for Smoking Cessation. In 1996, the NCCN only had 10 guidelines: breast cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, acute myelogenous leukemia, prostate cancer, ovarian cancer, pediatric neuroblastoma, pediatric osteosarcoma, and pediatric acute lymphoblastic leukemia.
“Looking back at those guidelines now, they were both complicated and visionary for 1996 and simple in comparison to today’s guidelines,” Dr Carlson said. “If we look just at the original 7 adult guidelines and compare them with their 2015 versions, it is remarkable how the guidelines and guidelines panels have expanded.”
Celebrating 20 years, Dr Carlson spent some time looking back at the history of NCCN, which was formed at a time when academic cancer centers were facing a number of threats, including the health maintenance organization movement and outside forces looking to dictate to physicians and patients on the care provided.
During this time, the guidelines were born, so that the original member institutions could assure that academic cancer centers would have a central role in deciding optimal and appropriate cancer care.
“The vision was to utilize the guidelines as a way of convincing payers that the academic centers provided effective and efficient care,” he explained.
Providing the guidelines free of charge was crucial, although controversial at the time. There were more than 6 million downloads of the guidelines in 2014. He attributes the rapid adoption of the guidelines to their use of graphical displays across the continuum of care, which makes them intuitive for clinicians to use.
Dr Carlson added that the guidelines have not been without controversy. For example, he explained the controversy from the first and second annual meetings surrounding the use of high-dose chemotherapy with bone marrow transplant in the treatment of metastatic breast cancer.
Today, the guidelines can be criticized for having too many options and too much choice; however, he feels these are a strength of the guidelines as they provide a range of choices for the best treatment among a range of appropriate options.
They are continuing to improve upon the guidelines, and one challenge in using the guidelines has been comparing multiple diagnostic and treatment options in an efficient manner. He acknowledged that patients have different value systems and priorities when they select a treatment. One may focus on effectiveness over safety and cost, while another only cares about cost. As a result, NCCN has developed a method of displaying efficacy, safety, quality of evidence, consistency of evidence, and affordability that will allow clinicians to quickly scan through options and focus on the one that best fits their patient’s preferences.
“As strong as the NCCN Guidelines are, we are not satisfied with where we are,” Dr Carlson said. “There are several initiatives that will transform the use and impact of the NCCN guidelines over the next few years.”
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More